Changes in understanding regarding the relationship of androgens and prostate cancer have led to changes in the use of testosterone therapy. The evidence supports a finite ability of androgens to stimulate prostate cancer growth, with a maximum achieved at low testosterone concentrations, called the saturation model. The saturation point corresponds with maximal androgenic stimulation at 250 ng/dL. Evidence is reviewed herein regarding the relationship of testosterone to prostate cancer and the relatively new practice of offering testosterone therapy to men with a history of prostate cancer. Although no prospective controlled trials have been performed, results have been reassuring.
The Urologic clinics of North America. 2016 May [Epub]
Emily Davidson, Abraham Morgentaler
Men's Health Boston, Department of Surgery (Urology), Harvard Medical School, 200 Boylston Street, Suite A309, Chestnut Hill, MA 02467, USA., Men's Health Boston, Department of Surgery (Urology), Harvard Medical School, 200 Boylston Street, Suite A309, Chestnut Hill, MA 02467, USA. Electronic address: .